Greenbrook TMS (NASDAQ:GBNH) Downgraded by Zacks Investment Research to “Sell”

Zacks Investment Research cut shares of Greenbrook TMS (NASDAQ:GBNHGet Rating) from a hold rating to a sell rating in a report published on Wednesday morning, Zacks.com reports.

According to Zacks, “Greenbrook TMS Inc. is a provider of Transcranial Magnetic Stimulation therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, principally in the United States. Greenbrook TMS Inc. is based in TORONTO. “

A number of other equities research analysts also recently weighed in on GBNH. Bloom Burton reissued a buy rating on shares of Greenbrook TMS in a report on Monday, April 4th. Canaccord Genuity Group downgraded Greenbrook TMS to a buy rating in a report on Monday, February 7th. Finally, Clarus Securities dropped their target price on Greenbrook TMS from C$8.25 to C$7.50 in a report on Monday, April 4th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Greenbrook TMS currently has a consensus rating of Buy and a consensus target price of $14.32.

Shares of Greenbrook TMS stock opened at $2.52 on Wednesday. The firm’s fifty day simple moving average is $3.13. Greenbrook TMS has a 1 year low of $2.42 and a 1 year high of $13.89. The firm has a market cap of $44.77 million and a P/E ratio of -1.57. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 2.26.

Greenbrook TMS (NASDAQ:GBNHGet Rating) last announced its quarterly earnings results on Wednesday, March 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.04. Greenbrook TMS had a negative return on equity of 189.28% and a negative net margin of 47.42%. During the same quarter in the prior year, the business posted ($0.60) earnings per share. As a group, sell-side analysts expect that Greenbrook TMS will post -1.21 EPS for the current year.

Institutional investors have recently modified their holdings of the company. Royal Bank of Canada lifted its holdings in shares of Greenbrook TMS by 243.1% during the 3rd quarter. Royal Bank of Canada now owns 6,848 shares of the company’s stock worth $51,000 after acquiring an additional 4,852 shares during the period. Rockefeller Capital Management L.P. bought a new stake in shares of Greenbrook TMS during the 3rd quarter worth approximately $109,000. AdvisorShares Investments LLC lifted its holdings in shares of Greenbrook TMS by 365.5% during the 4th quarter. AdvisorShares Investments LLC now owns 64,214 shares of the company’s stock worth $281,000 after acquiring an additional 50,418 shares during the period. Virtu Financial LLC bought a new stake in shares of Greenbrook TMS during the 4th quarter worth approximately $288,000. Finally, Royce & Associates LP lifted its stake in Greenbrook TMS by 8.0% in the 4th quarter. Royce & Associates LP now owns 223,500 shares of the company’s stock valued at $977,000 after purchasing an additional 16,598 shares during the last quarter. 16.73% of the stock is owned by institutional investors.

Greenbrook TMS Company Profile (Get Rating)

Greenbrook TMS Inc, together with its subsidiaries, controls and operates a network of outpatient mental health services centers in the United States. Its centers specialize in the provision of transcranial magnetic stimulation (TMS) therapy, an FDA-cleared non-invasive therapy for the treatment of major depressive disorder and other mental health disorders, as well as related psychiatric services.

Further Reading

Get a free copy of the Zacks research report on Greenbrook TMS (GBNH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Greenbrook TMS (NASDAQ:GBNH)

Receive News & Ratings for Greenbrook TMS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenbrook TMS and related companies with MarketBeat.com's FREE daily email newsletter.